Clark Andrew R, Mauntel Timothy C, Goldman Stephen M, Dearth Christopher L
Research and Surveillance Division, DoD-VA Extremity Trauma and Amputation Center of Excellence, Bethesda, MD, United States.
Department of Surgery, Uniformed Services University of the Health Sciences-Walter Reed National Military Medical Center, Bethesda, MD, United States.
Front Bioeng Biotechnol. 2023 Jan 9;10:1105599. doi: 10.3389/fbioe.2022.1105599. eCollection 2022.
Musculoskeletal injuries (MSKIs) are a great hindrance to the readiness of the United States Armed Forces through lost duty time and reduced operational capabilities. While most musculoskeletal injuries result in return-to-duty/activity with no (functional) limitations, the healing process is often long. Long healing times coupled with the high frequency of musculoskeletal injuries make them a primary cause of lost/limited duty days. Thus, there exists an urgent, clinically unmet need for interventions to expedite tissue healing kinetics following musculoskeletal injuries to lessen their impact on military readiness and society as a whole. There exist several treatments with regulatory approval for other indications that have pro-regenerative/healing properties, but few have an approved indication for treating musculoskeletal injuries. With the immediate need for treatment options for musculoskeletal injuries, we propose a paradigm of Repurposing Existing Products to Accelerate Injury Recovery (REPAIR). Developing treatments repurposing existing therapeutics for other indications has shown monumental advantages in both cost effectiveness and reduced time to bring to market compared to novel candidates. Thus, undertaking the needed research efforts to evaluate the effectiveness of promising REPAIR-themed candidates has the potential to enable near-term solutions for optimizing musculoskeletal injuries recovery, thereby addressing a top priority within the United States. Armed Forces. Herein, the REPAIR paradigm is presented, including example targets of opportunity as well as practical considerations for potential technical solutions for the translation of existing therapeutics into clinical practice for musculoskeletal injuries.
肌肉骨骼损伤(MSKIs)通过导致执勤时间损失和作战能力下降,极大地阻碍了美国武装部队的战备状态。虽然大多数肌肉骨骼损伤在恢复执勤/活动时没有(功能)限制,但愈合过程往往很长。愈合时间长加上肌肉骨骼损伤的高发性,使其成为执勤天数损失/受限的主要原因。因此,迫切需要临床上尚未满足的干预措施,以加快肌肉骨骼损伤后的组织愈合动力学,减轻其对军事战备状态乃至整个社会的影响。有几种经监管批准用于其他适应症的治疗方法具有促再生/愈合特性,但很少有被批准用于治疗肌肉骨骼损伤的适应症。鉴于对肌肉骨骼损伤治疗方案的迫切需求,我们提出了一种“重新利用现有产品加速损伤恢复(REPAIR)”的模式。与新型候选药物相比,开发将现有治疗药物用于其他适应症的治疗方法在成本效益和缩短上市时间方面都显示出巨大优势。因此,开展必要的研究工作来评估有前景的以REPAIR为主题的候选药物的有效性,有可能为优化肌肉骨骼损伤恢复提供近期解决方案,从而解决美国武装部队的一项首要任务。在此,介绍了REPAIR模式,包括潜在机会的示例目标以及将现有治疗药物转化为肌肉骨骼损伤临床实践的潜在技术解决方案的实际考虑因素。